These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Advanced findings on the molecular mechanisms for behavioral sensitization to psychostimulants]. Ujike H Nihon Yakurigaku Zasshi; 2001 Jan; 117(1):5-12. PubMed ID: 11233297 [TBL] [Abstract][Full Text] [Related]
4. [Dynamics and functional analysis of cytokines/proteinases with drug dependence]. Yamada K Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Nov; 28(5-6):195-201. PubMed ID: 19108506 [TBL] [Abstract][Full Text] [Related]
5. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Sekine Y; Iyo M; Ouchi Y; Matsunaga T; Tsukada H; Okada H; Yoshikawa E; Futatsubashi M; Takei N; Mori N Am J Psychiatry; 2001 Aug; 158(8):1206-14. PubMed ID: 11481152 [TBL] [Abstract][Full Text] [Related]
6. Pro-addictive and anti-addictive factors for drug dependence. Yamada K Nagoya J Med Sci; 2008 Aug; 70(3-4):67-72. PubMed ID: 18954024 [TBL] [Abstract][Full Text] [Related]
7. Endogenous modulators for drug dependence. Yamada K Biol Pharm Bull; 2008 Sep; 31(9):1635-8. PubMed ID: 18758051 [TBL] [Abstract][Full Text] [Related]
8. Drug dependence, synaptic plasticity, and tissue plasminogen activator. Yamada K; Nagai T; Nabeshima T J Pharmacol Sci; 2005 Feb; 97(2):157-61. PubMed ID: 15684570 [TBL] [Abstract][Full Text] [Related]
9. [Regulation by tissue plasminogen activator of rewarding effects of drugs of abuse]. Nagai T; Takuma K; Nabeshima T; Yamada K Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Feb; 28(1):1-6. PubMed ID: 18411702 [TBL] [Abstract][Full Text] [Related]
10. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Frey K; Kilbourn M; Robinson T Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358 [TBL] [Abstract][Full Text] [Related]
12. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Wilson JM; Levey AI; Bergeron C; Kalasinsky K; Ang L; Peretti F; Adams VI; Smialek J; Anderson WR; Shannak K; Deck J; Niznik HB; Kish SJ Ann Neurol; 1996 Sep; 40(3):428-39. PubMed ID: 8797532 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Fleckenstein AE; Gibb JW; Hanson GR Eur J Pharmacol; 2000 Oct; 406(1):1-13. PubMed ID: 11011026 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of reserpine on dopamine transporter function. Metzger RR; Brown JM; Sandoval V; Rau KS; Elwan MA; Miller GW; Hanson GR; Fleckenstein AE Eur J Pharmacol; 2002 Dec; 456(1-3):39-43. PubMed ID: 12450567 [TBL] [Abstract][Full Text] [Related]
15. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system. Wilhelm CJ; Johnson RA; Lysko PG; Eshleman AJ; Janowsky A J Pharmacol Exp Ther; 2004 Sep; 310(3):1142-51. PubMed ID: 15102929 [TBL] [Abstract][Full Text] [Related]
16. Genes and molecules that can potentiate or attenuate psychostimulant dependence: relevance of data from animal models to human addiction. Niwa M; Yan Y; Nabeshima T Ann N Y Acad Sci; 2008 Oct; 1141():76-95. PubMed ID: 18991952 [TBL] [Abstract][Full Text] [Related]
17. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Harvey DC; Laćan G; Melegan WP Exp Brain Res; 2000 Aug; 133(3):349-58. PubMed ID: 10958525 [TBL] [Abstract][Full Text] [Related]
18. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Shen HW; Hagino Y; Kobayashi H; Shinohara-Tanaka K; Ikeda K; Yamamoto H; Yamamoto T; Lesch KP; Murphy DL; Hall FS; Uhl GR; Sora I Neuropsychopharmacology; 2004 Oct; 29(10):1790-9. PubMed ID: 15226739 [TBL] [Abstract][Full Text] [Related]
19. Addiction as a brain disease. Kosten TR Am J Psychiatry; 1998 Jun; 155(6):711-3. PubMed ID: 9619141 [No Abstract] [Full Text] [Related]
20. Upregulation of tumor necrosis factor-alpha in nucleus accumbens attenuates morphine-induced rewarding in a neuropathic pain model. Wu Y; Na X; Zang Y; Cui Y; Xin W; Pang R; Zhou L; Wei X; Li Y; Liu X Biochem Biophys Res Commun; 2014 Jul; 449(4):502-7. PubMed ID: 24845379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]